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Abstract
Mutations in one of the DNA repair genes are one of the most common reasons for cancer, and it may be assumed that the
individual genetic background modulating the DNA repair capacity may affect the susceptibility to cancer. Numerous poly-
morphisms (mainly SNPs) have been identified for DNA repair genes, although their functional outcome and phenotypic effect is
often unknown. The aim of the present review is to evaluate the studies investigating a possible influence of DNA repair
polymorphisms in the risk of sporadic colorectal cancer and/or adenoma. Overall, no relevant common findings emerge among the
studies, except for some statistically significant associations between polymorphisms in the XRCC1 and XPD genes, mainly for
colorectal adenoma risk. Other individual associations remain to be confirmed. This inconclusive data may suggest that the
modulation of cancer risk depends not only on a single gene/SNP, but also on a joint effect of multiple polymorphisms (or
haplotypes) within different genes or pathways, in close interaction with environmental factors. The relevance of many low-
penetrance genes in cancer susceptibility is supposed to be very subtle. Several reviewed association studies revealed weaknesses in
their design. However, there has been a progressive improvement over the years in aspects such as simultaneous genotyping and
combined analyses of different polymorphisms in larger numbers of patients and controls, as well as stratification of results by
ethnicity, gender, and tumor localization. This gained experience shows that only carefully designed studies of a sufficient statistical
power may resolve the relationships between polymorphisms and colorectal cancer risk.
# 2007 Elsevier B.V. All rights reserved.
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1. Introduction
1.1. Colorectal cancer: relevance and causes
Colorectal carcinoma (CRC) is one of the most
frequent causes of cancer death in industrialized
countries for both men and women, with a yearly
incidence of about 50 new cases for every 100,000
people in the population [1]. The prevalence of CRC has
been steadily increasing over the last century, while
mortality rates have declined as a result of improved
treatment and efficient screening and surveillance [2].
Stratification of the population into risk categories for
CRC onset could enable targeted prevention, with
measures tailored according to individual risk levels. To
achieve this goal, relationships between individual
genetic background and the relevance of non-genetic
factors along with CRC pathogenesis need to be
thoroughly explored [3,4].
CRC is traditionally divided into sporadic and
familial (hereditary) forms [5] and represents a complex
disease, whose development is determined by different
combinations of genetic and environmental factors [8].
Genetic syndromes (familial adenomatous polyposis-
FAP, Peutz-Jeghers syndrome, Juvenile polyposis and
hereditary non-polyposis colon cancer-HNPCC)
account for only 3% of all cases [7]. The majority of
cases are sporadic or show a pattern of familial
aggregation, not easily fitting into models of Mendelian
inheritance [6]. Rare and highly penetrant mutations in
cancer genes may act with little environmental
influence, while a complex interplay of genetic and
environmental factors is expected in the development of
sporadic CRC. Several epidemiological studies have
highlighted the role of diet and lifestyle in CRC risk in
the last 40 years: positive correlations have been
reported with the intake of fat, red meat and alcohol, as
well as smoking [9,10], and inverse correlations with
the intake of vegetables and fibres [11,12]. Other non-
dietary environmental life-style and supplementary
factors with protective effects include: high physical
activity, hormone replacement therapy (HRT) in
postmenopausal females, and the regular use of non-
steroidal anti-inflammatory drugs (NSAIDs), such as
aspirin [13,14]. Several of these associations (in
particular for NSAIDs) are considered as consistent
and biologically plausible; however, the causality is not
fully understood. Sporadic CRC development requires a
complex interaction between genetic and specific
environmental/life style risk factors with different
degrees of involvement. A net distinction between
‘genetic’ and ‘environmental’ predisposing factors is
virtually impossible – a more realistic approach appears
to be a continuum of risks contributing to sporadic
CRC. CRC onset is likely to involve multiple genes with
moderate effects (low penetrance type) and progress
materializes due to aggressive gene-environment inter-
actions [6,15].
1.2. Importance of low-penetrance genes in CRC
The identification of genetic polymorphisms (the
occurrence in the same population of multiple discrete
allelic states of which at least two have high frequency,
conventionally of 1% or more) has stimulated
hypotheses to explain the high degree of observed
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individual variability in cancer susceptibility [16]. The
successful sequencing of the human genome has
provided the identification of a large number of low-
penetrance alleles and molecular epidemiology has
acquired the technological device for design large-scale
case-control association studies. However, many results
from epidemiologic studies have been inconsistent due
to: (1) the small size of analyzed cohorts resulting in a
low statistical power for detecting moderate effects, (2)
false-positive results, (3) heterogeneity across study
populations (ethnic differences in genetic background),
(4) failure to consider effect modifiers such as
environmental exposures, and (5) publication bias
versus negative results [17]. In addition, mainly lacking
in the association studies is the identification of
biologically plausible functional reflections of many
polymorphisms, as well as gene–gene and gene-
environment interactions [18].
In the case of sporadic CRC, the number of relevant
candidate genes with high-frequency low-penetrance
alleles is wide [6,19]. A brief report of the main
pathways follows.
1.2.1. Biotransformation
The general host metabolic status represents an
important factor in modulating cancer progression [20].
Chen et al. [21] reported recently a meta-analysis on
association studies between xenobiotic metabolism
enzyme polymorphisms and CRC risk: GSTT1 deletion
appears as a main risk factor along with NAT2-rapid
acetylator phenotype and genotype.
1.2.2. Methylation
Imbalanced DNA methylation, characterized by
genomic hypomethylation and methylation of usually
unmethylated CpG sites, is consistently observed in
CRC [22]. MTHFR C677Tand A1298C polymorphisms
in the most important gene involved in DNA methyla-
tion and synthesis have recently been analyzed in
association with adenoma and CRC risk. A decreased
risk has been observed for carriers of the 677TT
genotype, independently from the low/high folate status
[23].
1.2.3. Immune response genes
Chronic inflammation is considered as a crucial
factor in CRC development, since it affects key cellular
processes like proliferation, adhesion, apoptosis,
angiogenesis, and transformation. Cytokine-encoding
genes influence inter-individual variation in the
magnitude of inflammatory response, and variants of
proinflammatory cytokines IL6, IL8, and IL10 have
been associated with CRC risk [24–26]. Prostaglandin
H synthase (PTGS) and peroxisome proliferator-
activated receptor g (PPARG), were also studied in
relation to CRC. A variant allele in the PTGS2 promoter
region has been associated with colorectal adenoma
among non-NSAID users [27], while a nonsynonymous
amino acid substitution in PPARG exon 12 has been
associated with adenoma and CRC risk [24,28].
1.2.4. Oncogenes and tumor suppressor genes
Low-penetrance variants in high-penetrance genes
might also be important in sporadic CRC. The APC
I1307K polymorphism represents the strongest case for
a susceptibility allele conferring increased CRC risk.
The aminoacidic change does not alter the functional
properties, but the underlying DNA sequence change
(T!A) generates a short hypermutable poly-A repeat
[29]. This mechanism increases the likelihood for
occurrence of the first somatic hit (APC sequence
frameshifts), affecting CRC risk. A higher frequency of
APC 1307K variant has been reported among Ashke-
nazi descendants, corresponding to an approximately
two-fold lifetime risk of CRC compared to the general
population [30].
1.2.5. Cell cycle
The Tp53 gene plays a fundamental role in
preventing the replication of damaged DNA [31].
The most frequently studied Tp53 R72P polymorphism
provided conflicting results in relation to CRC [32,33].
Recently, Koushik et al. [34] have found an association
of 72P allele with increased adenoma risk, suggesting
R72P SNP being involved in the early stages of
colorectal neoplasia and possibly in progression to
invasive disease, depending on site and sex. Intronic
sequences in TP53, regulate gene expression and DNA-
protein interactions [35]. Intron 3 variant allele carriers
showed a decreased CRC risk [32,33]. Cyclin D1 is a
key cell cycle regulatory protein with altered expression
and subcellular localization in human tumor cells.
Cyclin D1 A870G is associated with two distinct mRNA
transcripts for G1/S regulatory protein [36], and results
in conflicting associations with adenoma and CRC risk
in several studies [37–40].
1.3. Possible role of DNA repair individual
susceptibility
The genome is continuously attacked by endogenous
and exogenous mutagens. Several responses follow
DNA damage recognition to prevent replication in the
presence of genetic errors: checkpoints activation to
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arrest the cell cycle, transcription up-regulation to
compensate for the damage, or apoptosis. Alternatively,
the damage can be repaired at the DNA level enabling
the cell to replicate. The maintenance of genomic
integrity is thus of primary importance in the general
and specialized functions of cells, as well as in the
prevention of carcinogenesis [41,42].
Mutations in mismatch repair (MMR) genes are
known to segregate in families with HNPCC [43]. In
addition, the identification of germline mutations in
base excision repair (BER) gene MUTYH in individuals
with a predisposition to multiple colorectal adenomas
and carcinomas has highlighted the relevance of DNA
repair in CRC development [44]. Individual differences
in DNA repair capacity pose an important issue in CRC
etiology, despite still inadequate specific functional
assays for assessing intra- and inter-individual varia-
bility [45]. The polymorphisms of genes involved in
different DNA repair pathways may modulate the
individual repair capacity in response to DNA damage,
and may have an impact on individual genetic
susceptibility to basically all types of cancer, including
CRC [46]. The possible role of DNA repair individual
susceptibility is schematically shown in Fig. 1. Over
520 amino acid substitution variants in 91 DNA repair
genes have been identified in humans, while the number
of other silent polymorphisms is constantly increasing,
with many of them still unknown [47]. An analysis of
SNPs in 88 DNA repair genes and their functional
evaluation, based on the conservation of amino acids
among the protein family members, shows that
approximately 30% of variants of DNA repair proteins
are likely to affect substantially the protein function
[48]. For many polymorphisms, the functional sig-
nificance/phenotypic changes are not experimentally
proven in the general population. Few existing studies
employed ionizing radiation sensitivity or cytogenetic
challenge assay for evaluation of individual DNA repair
capacity. Polymorphisms in XRCC1 R194Wand R399Q
appear to modulate significantly markers of DNA and
chromosomal damage [49,50] and these data seem to be
biologically plausible [51]. Conflicting results have
been reported on the impact of OGG1 S326C [52–54],
although this polymorphism seems to affect the
glycosylase function due to the localization and
phosphorylation status [55]. Recently, decreased irra-
diation-specific DNA repair rates were observed in
cancer-free individuals with XRCC1 399QQ variant
genotype, consistent with a role of the gene in BER
pathway. In addition, the capacity to repair oxidative
DNA damage was significantly decreased in individuals
with OGG1 326CC variant genotype. Combined variant
A. Naccarati et al. / Mutation Research 635 (2007) 118–145 121
Fig. 1. The tentative role of individual genetic susceptibility along with external/internal environmental factors in sporadic CRC risk. Among
several pathways potentially involved in the modulation of cancer development, due to the variability in their low-penetrance genes, a particular
importance may be attributable to DNA repair. The individual DNA repair capacity, as evicted by the schema, is the result of complex interplay
between genes of different DNA repair pathways, in which particular polymorphisms/haplotypes in combination may contribute to alter the ultimate
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alleles of XRCC1 R399Q, R194W and R280H and
APE1 D148E resulted in a decrease of irradiation-
specific repair rates, reflecting a SNP-SNP interaction.
Combined variant alleles of OGG1 S326C and APE1
D148E decreased the repair of DNA oxidative damage
as well [56]. The above studies may contribute to the
more meaningful choice of genes/polymorphisms for
association studies. Several reviews have recently tried
to summarize the main results of the studies on DNA
repair genetic polymorphisms in association with
cancer [54,57–60]. However, the outcomes from
epidemiological studies are ambiguous. Only in the
case of OGG1 and XRCC1 for BER and XPD for
nucleotide excision repair (NER), consistent evidences
for association of particular genetic polymorphisms
with specific cancers have been found. OGG1 S326C
variant allele seems to be associated with increased risk
of lung, esophagus, and prostate cancer [54,57,58],
while SNPs of XPD have been associated with skin,
breast and lung cancer [59,60].
In the case of CRC, association studies with DNA
repair polymorphisms have not yet been comprehen-
sively and critically reviewed. In order to enable an
understanding of the current knowledge, the following
paragraphs will analyse in detail all association studies
available on DNA repair polymorphisms and sporadic
CRC.
2. Methods
We reviewed a total of 25 association studies between
DNA repair polymorphisms and ha lotypes and risk of CRC.
We evaluated available studies from Pub Med (http://
www.ncbi.nlm.nih.gov/), without any exclusion. Among these
studies, a few considered individuals with both adenomas and
sporadic CRC, or with adenomas only. We also included these
studies, since adenomas are considered important precursors
of CRC. SNPs addressed in the reviewed studies are listed in
Table 1. They are organized by DNA repair pathways in which
the corresponding genes are involved. Table 1 provides,
whenever possible, frequencies for the variant allele in the
A. Naccarati et al. / Mutation Research 635 (2007) 118–145122
Table 1
Description of DNA repair polymorphisms investigated in the studies reviewed
DNA repair
pathway




NER XPD (ERCC2) IVS19-70 IVS19-70, G! A 0.29
D312N Ex 10, G! A 0.33–0.37
K751Q Ex 23, A! C 0.07–0.39
R156R Ex 6, C! A 0.39
D711D Ex 22, C! T 0.36
XPF (ERCC4) P379S Ex 7, C! T 0.001–0.004
R415Q Ex 8, G! A 0.07–0.11
E875G Ex 11, A! G n.a.
Codon 824 (?)b Ex 11, T! C 0.14
S662P Ex 10–34, T! C 0.003
XPG (ERCC5) M254V Ex 7, A! G 0.03
335 T! C (H46H) Ex 2, T! C 0.4
C529S Ex 8, G! C 0.04–0.05
D1104H Ex 15, G! C 0.21–0.28
XPC R492H Ex 8, G! A 0.06
A499V Ex 8, C! T 0.23–0.24
R687R Ex 11 + 28, G! A 0.27
K939Q Ex 16, A! C 0.40–0.42
RAD23B (hHR23B) A249V Ex 7, C! T 0.17–0.20
CSB (ERCC6, RAD26) M1097V Ex 18, A! G 0.19–0.21
R1230P Ex 18, G! C 0.10–0.11
Q1413R Ex 21, A! G 0.19
R1213G Ex18-142, A!G 0.20
CCNH (CAK) V270A Ex 8, T! C 0.20
ERCC1 (UV20) 19716 C! G IVS3 + 74, C! G 0.35–0.37
19007 T! C (N118N) Ex 4, T! C 0.38
17677 A! C IVS5 + 33, A! C 0.11
15310 G! C G! C 0.08
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Table 1 (Continued )
DNA repair
pathway




(?)b Ex 4, G! A 0.40
Q504K 196 bp 30 of STP, T! G 0.26
XPA (XP1) 30UTR C! G Ex 6-327, C! G Rare
XPB (ERCC3) 487 bp 30 of STP, G! A 487 bp 30 of STP, G! A 0.36
IVS6-108, A! C IVS6-108, A! C 0.34
RPA2 30UTR T! C Ex 9-51, T! C 0.36
LIG1 50UTR C! T Ex 2-24, C! T 0.13
BER OGG1 (MUTM) R154H G! T 0.003
S326C Ex 6, C! G 0.19–0.52
XRCC1 R194W Ex 6, C! T 0.05–0.32
R280H Ex 9, G! A 0.02–0.09
R399Q Ex 10, G! A 0.14–0.39
Q632Q Ex 17, G! A 0.42
LIG3 K811T Ex 15, A! C 0.002
R780H Ex 18, G! A 0.002
APEX (APE1) Q51H Ex 3, G! C 0.03
D148E Ex 5, T! G 0.45
POLB P242R Ex 12, C! G 0.01
PCNA 1876 A! G A! G 0.13
MUTYH Y165C n.a. Rare
G382D n.a. 0.01
DSB Repair XRCC3 T241M Ex 8, C! T 0.02–0.45
4541 A! G A! G 0.19
17893 A! G A! G 0.32
NBS1 (NBN, ATV) E185Q Ex 5, C! G n.a.
XRCC2
XRCC9 (FAG, FANCG) R188H Ex 3, G! A 0.07–0.09
T297I Ex 7, C! T 0.009
Direct repair MGMT L84F Ex 2, C! T 0.12–0.14
171 C! T (L53L) Ex 2, C! T 0.13
I143V Ex 4, A! G 0.10–0.12
Mismatch repair EXO1 T439M Ex 12, C! T 0.10
P757L Ex 15, C! T 0.46
MLH1 (HNPCC2) 93 G! A Promoter G! A 0.22
I219V Ex 8, A! G 0.03–0.33
V384D Ex 12, T!A 0.03
hMSH3 T1036A Ex 23 + 3G! A 0.28
R940Q Ex 21, G! A 0.15
hMSH2 (HNPCC1) L390F Ex 5, C! T 0.02
IVS12 IVS12, C! T 0.4
hMSH6 (HNPCC5) G39E Ex 1 G! A 0.17–0.18
V509A Exon 4, T! C Rare
159 C! T Promoter, C! T 0.01
a Frequency of variant allele among control populations in association studies cited in this review.

















































Association studies between genetic polymorphisms in NER genes and risk of CRC/adenomas
Reference Genes (polymorphisms) Cases Controls Ethnicity (country) Associations Interactions
Berndt et al. [62] XPA (30UTR C! G)







CSB (M1097V, R1213G, R1230P)
LIG1 (50UTR C! T)
ERCC1 (Q504K, 19716 C ! G)
RAD23B (A249V)
RPA2 (30UTR T! C)





CSB 1097V and 1213G








with " CRC risk
SNP-SNP interaction
between CSB 1097V and
XPC 492H alleles and CSB
1213G and XPC 492H
alleles slightly " CRC risk
CSB 1097V and 1213G alleles
associated with " CRC risk
among individuals with a first-
degree relative with CRC
No interactions with
age at diagnosis, gender,
smoking habit, red meat
intake, folate intake,
and body mass index
Goodman et al. [64] XPD (D312N) 216 carcinomas
(males)












Huang et al. [72] XPD (D312N, K751Q)
XPC (R492H, A499V, K939Q)
RAD23B (A249V)
CSB (M1097V, R1230P, Q1413R)
CCNH (V270A)
XPF (P379S, R415Q)











haplotype (R, A, and Q)
associated with " risk
of high-risk adenomas
No interactions with age,
gender, and ethnicity
Moreno et al. [63] ERCC1 (19716 G! C,
19007 T! C, 17677 A! C,
15310 G! C, 8092 C! A)
377 carcinomas 329 hospital
healthy
Caucasian (Spain) ERCC1 17677C allele
associated with " CRC
risk in an additive model
No interactions with age
XPD (D312N, K751Q) ERCC1 haplotype
(19716C, 19007C and
17677C) associated
with " CRC risk
XPF (P379S, R415Q)
XPG (335 T! C)
Skjelbred et al. [70] XPD (K751Q) 157 carcinomas 399 negative to
colonscopy
screening
Caucasian (Norway) XPD 751Q allele






















































Skjelbred et al. [71] ERCC1 (N148N) 156 carcinomas 399 negative
to colonscopy
screening
Caucasian (Norway) No association
of single SNP





Bigler et al. [73] XPD (D312N, K751Q) 694 (384 adenomatous
polyps, 191 hyperplastic








Heavy smokers with XPD
combined homozygous
variant genotypes or XPG
1104DD genotype had an "
risk of adenomatous polyps
XPG (D1104H)
Combination of XPD




associated with # risk of
hyperplastic polyps in young
individuals (<60 years)
XPG 1104HH genotype
associated with # risk
of hyperplastic polyps
No interactions with
gender, meat consumption, and
alcohol and vitamin intakes






XPD 751Q allele associated
with age at diagnosis in
Ashkenazi subset only
Yeh et al. [65–67] XPD (K751Q) 727 carcinomas 736 negative to
colonscopy
screening
Asian (Taiwan) No association
of single SNP
" CRC risk for combinations
of XPD, XRCC3, and XRCC1
genotypes with OR > 1,
particularly for younger
individuals (<61 years) and
for rectum cases
Combinations of XPD and
CYP1A1*2C and GSTT1
deletion high-risk genotypes
associated with " CRC risk
No interactions for XPD
polymorphism with
smoking habit, alcohol
and meat intake, or vegetable/
fruit and fish/shrimp consumption
Mort et al. [69] XPD (exon 6, exon 22,
K751Q)
45 carcinomas 71 hospital healthy

























































Association studies between genetic polymorphisms in BER genes and risk of CRC/adenomas
Reference Genes (polymorphisms) Cases Controls Ethnicity (country) Associations (main results) Interactions









No interactions between BER
(or other DNA repair)
polymorphisms
XRCC1 (R194W, R399Q)






PCNA (1876 A! G)
MUTYH (Y165C, G382D)
377 carcinomas 329 hospital
healthy




associated with " CRC
risk in young individuals
POLB 242R rare allele
associated with # CRC
risk (no homozygous
variant found)
XRCC1 194W and 280H
minor alleles associated
with a # CRC risk in
young individuals
Skjelbred et al. [70] XRCC1 (R194W,
R280H, R399Q)
157 carcinomas 399 negative to
colonscopy
screening








XRCC1 399Q allele associated
with # risk in the high-risk
adenoma group
Hansen et al. [78] OGG1 (S326C) 166 carcinomas 397 negative to
colonscopy
screening
Caucasian (Norway) OGG1 326C allele associated
with # carcinoma risk
974 adenomas
Hong et al. [40,74] XRCC1 (R194W,
R280H, R399Q)
209 carcinomas 209 hospital
healthy
Asian (South Korea) XRCC1 399Q allele associated
with " CRC risk
" CRC risk associated




The combined alleles XRCC1
194W-280R-399Q associated
with " CRC risk
No interaction with smoking,
dietary habits and physical
activity
Stern et al. [79] XRCC1 (R194W,
R399Q)









" Adenoma risk associated
with high monounsaturated



















































XRCC1 194RR and 399QQ
combined genotypes





Yeh et al. [65–67] XRCC1 (R399Q) 727 carcinomas 736 negative to
colonscopy
screening
Asian (Taiwan) No association of single SNP XRCC1 399R allele
associated with " CRC
risk for young individuals
(<61yrs) and for rectum cases









and meat intake, or
vegetable/fruit and
fish/shrimp consumption
Kim et al. [80,86] OGG1 (R154H) 500 carcinomas 527 hospital healthy Asian (South Korea) OGG1 154H allele associated
moderate " CRC risk
Krupa and Blasiak [77] XRCC1 (R399Q) 51 carcinomas 100 hospital healthy Caucasian (Poland) XRCC1 399Q allele (?) weakly
associated with " CRC risk
Gene–gene interaction
between the XRCC3
241MM and the XRCC1
399RR genotypes
slightly " CRC risk
Kim et al. [76] OGG1 (S326C) 125 carcinomas 247 cancer-free Asian (South Korea) No association of single SNP OGG1 326CC genotype
associated with " CRC
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control population to facilitate the comparisons among stu-
dies. Results section and Tables 2–6 are organized according
to the different DNA repair pathways and summarize main
characteristics and main outcomes of reviewed epidemiolo-
gical studies. They are listed chronologically. Some of the
studies analyzed simultaneously several polymorphisms in
different DNA repair pathways, sometimes evaluating the
results from polymorphisms in combination: in this case,
studies were reported separately for each DNA repair pathway
and the overlapping outcomes were specified. The main
interactions with confounders were also highlighted from
each study and reported in Tables 2–6. Present review focuses
primarily on the association with DNA repair SNPs, while
stressing an importance of gene-environmental interactions in
the future studies.
The comparative funnel plots (Figs. 2–4) were constructed
for SNPs (XPD K751Q, XRCC1 R399Q and XRCC3 T241M)
most frequently studied for associations with adenoma or CRC
risk. We included the crude odds ratios (OR) for the homo-
zygous variant genotype, considering the homozygous wild-
type genotype as the referent. A brief section was dedicated to
the studies investigating the relationship between individual
susceptibility in DNA repair genes and the prognosis and
efficacy/toxicity of the therapy for CRC. The field of the
pharmacogenetics, although scarcely explored currently, may
be of interest in understanding the role of DNA repair poly-
morphisms in the secondary prevention to this type of cancer.
3. Results
3.1. Nucleotide excision repair (NER)
The NER pathway is the most versatile mechanism
of DNA repair, removing a large number of structurally
unrelated DNA lesions: bulky lesions such as pyrimi-
dine dimers, other photoproducts, larger chemical
adducts, and cross-links. Two distinct NER subpath-
ways have been recognized: global genome NER,
detecting and removing lesions throughout the whole
genome, and transcription-coupled NER, ensuring the
fastest repair of lesions located on the transcribed strand
of actively transcribed genes. The NER pathway
involves at least four steps: (a) damage recognition
by a complex of bound proteins including XPC; (b)
unwinding of the DNA by the TFIIH complex that
includes XPD; (c) removal of the damaged single-
stranded fragments (usually about 27–30 bp) by
molecules including an ERCC1 and XPF complex;
and (d) synthesis by DNA polymerases [46,61].
The complete list of NER genes and polymorphisms
investigated in all reviewed association studies on
adenoma and CRC risk is available in Table 1. In
Table 2, the 12 studies evaluating one or more
polymorphisms of NER genes are described.






























































































































































































































































































































































































Association studies between genetic polymorphisms in Double-strand break repair genes and risk of CRC/adenomas
Reference Genes (polymorphisms) Cases Controls Ethnicity (Country) Associations (Main results) Interactions
Goodman et al. [64] XRCC3 (T241M) 216 carcinomas
(males)






No interactions between DSB
(or other DNA repair) polymorphismsNBS1 (E185G)
Skjelbred et al. [70] XRCC3 (T241M) 157 carcinomas 399 negative to
colonscopy screening
Caucasian (Norway) No association
of single SNP
No interactions with smoking




Moreno et al. [63] XRCC2 (R188H) 377 carcinomas 329 hospital healthy Caucasian (Spain) No association
of single SNP
No interaction with age
XRCC3 (T241M)
XRCC9 (T297I)
Jin et al. [83] XRCC3 (T241M) 140 carcinomas 280 cancer-free Asian (China) XRCC3 241M
allele associated
with " CRC risk
XRCC3 241M allele in older
individuals associated with " CRC risk
Non smokers and non using alcohol
individuals with XRCC3 241M allele
associated with " CRC risk
No interaction with gender






No interactions with poly and mono
unsaturated fatty acids and antioxidant
intake
Yeh et al. [65–67] XRCC3 (T241M) 776 carcinomas 736 negative to
colonscopy screening
Asian (Taiwan) No association
of single SNP
XRCC3 241T allele associated with
" CRC risk in low meat consumption
individuals, particular in rectum cases
" CRC risk for combinations of XRCC3,
XPD and XRCC1 genotypes with OR >1,
particularly for younger individuals
(<61yrs) and for rectum cases
Combinations of XRCC3 T241M and
CYP1A1*2C high-risk genotypes associated
" CRC risk in women
No interactions with smoking habit,
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Berndt et al. [62] analysed very recently a total of 22
polymorphisms in 11 genes involved in NER pathway
in 250 CRC cases and 2224 controls. The CSB 1213G
and 1097V variant alleles were associated with a dose-
dependent increased risk of cancer in comparison with
the wild-type (P = 0.0005 and P = 0.001, respectively).
Both SNPs were found to be in strong linkage
disequilibrium (D0 = 1.0), so the effect of one poly-
morphism was not discernable from the other. XPC
492H variant allele was also associated with increased
CRC risk (P = 0.004) and haplotype analyses for four
XPC SNPs showed an association with CRC risk only
when 492H variant allele is present. CSB R1213G and
XPC R492H in combination revealed an increased CRC
risk followed increasing number of variant alleles
(Ptrend = 0.00003). Although the study was performed
on a cohort of mixed Americans, the authors stated that
Caucasians represented 98% of the population and also
considered ethnicity in the statistics.
Moreno et al. [63], investigated polymorphisms of
genes involved in several DNA repair pathways, in a
Spanish cohort of 377 CRC cases and 329 controls. The
authors considered a total of 10 polymorphisms in four
NER genes and they found a borderline association with
CRC risk for ERCC1 17677 A! C (P = 0.058) in an
additive model (i.e. combining variant + heterozygous).
The risk for selected ERCC1 haplotypes (19716 G! C,
19007 T! C, 17677 A! C, 15310 G! C, 8092
C! A) was also tested. The haplotype containing the
minor allele C of ERCC1 17677 A! C was significantly
associated with increased risk of CRC when compared
with the most frequent haplotype (OR, 2.32; 95% CI,
1.01–5.34). For all other NER polymorphisms analysed,
no other associations were observed.
Goodman et al. [64], exploring SNP-SNP interac-
tions and colon cancer risk, investigated 94 genes in
several pathways potentially involved in cancer devel-
opment. The authors developed a statistical polymorph-
ism interaction analysis to screen the most important
SNPs combinations. Among different DNA repair
polymorphisms, they investigated five SNPs in three
NER genes (XPD, XPF and XPG) in 216 cases and 255
controls (males only), but no association was found with
cancer risk. The study is interesting for the idea to
investigate a large set of SNPs and their possible
interactions, reflecting the real situation in the organ-
ism. However, the size of the population is rather
limited for this kind of analysis and the study included
different ethnicities (Caucasian and Afro-American),
precluding robust outcomes.
Two studies by Yeh and co-workers [65,66] analyzed
a cohort of 727 CRC patients and 736 controls from






































































































































































































































































































































































































































































































































































Association studies between genetic polymorphisms in Mismatch repair genes and risk of CRC/adenomas
Reference Genes (polymorphisms) Cases Controls Ethnicity (country) Associations (main results) Interactions






associated with " CRC risk
hMSH3 1036A allele associated with
" risk of CRC in interaction with




associated with " risk
of rectal cancer
hMSH3 haplotype containing
1036A allele associated with "
CRC risk among individuals
with processed meat intake
10 g/day
hMSH6 (G39E) hMSH3 haplotype containing
both 940Q and 1036A alleles
associated with " CRC risk
No interactions with gender,
smoking habit, folate intake,
and alcohol consumption, and
family history










No association of single SNP hMLH193 A allele is






EXO1 (T439M, P757L) 102 carcinomas 110 healthy
population
Asian (Japan) EXO1 439M allele associated
with " CRC risk
EXO1 757 LL genotype
associated with # CRC risk
EXO1 439MM and 439TM,
with EXO1 757PL genotypes
are associated with " CRC risk
Kim et al. [80,86] hMLH1 (I219V, V384D) 107 carcinomas 330 healthy controls
and 107 first degree
relatives of cases






167 carcinomas 190 healthy controls American Jews
(USA)

















































Association studies between genetic polymorphisms in MGMT gene (Direct repair) and risk of CRC/adenomas
Reference Genes (polymorphisms) Cases Controls Ethnicity (country) Associations
(main results)
Interactions






No interactions between MGMT
and other DNA repair
polymorphisms
Moreno et al. [63] MGMT (171 C! T,
L84F, I143V)
377 carcinomas 329 hospital healthy Caucasian (Spain) No association
of single SNP
No interactions with age
Bigler et al. [73] MGMT (L84F, I143V) 694 (384 adenomatous
polyps, 191 hyperplastic








showed an interaction with
smoking habit
No interactions with age, gender,
meat consumption, and alcohol
and vitamin intake
Tranah et al. [93]
MGMT (L84F, I143V)






with # risk of CRC
in cohort of women
MGMT 84F allele associated
with " risk of CRC among
women consuming 0.5
drink/day. No interaction





single SNP in men
cohort
MGMT 84F and 143V alleles
associated with # risk of CRC
among women with BMI 25
MGMT 84LL genotype and
use of postmenopausal hormone
associated with " risk of CRC
No interactions with smoking habit,
folate, and processed meat intake
in women
No interactions with BMI,
alcohol consumption,
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A. Naccarati et al. / Mutation Research 635 (2007) 118–145 133
Fig. 2. Odds ratios for the relation between XPD K751Q polymorphism, adenoma (A) and CRC (B) risk in the reviewed studies. For each study, the
odds ratio for the homozygous variant genotype estimated is plotted with a box, and the area of each box is inversely proportional to the variance of
the estimated effect. Horizontal lines show 95% confidence interval. Individuals with homozygous wild-type genotype represent a referent group.
Fig. 4. Odds ratios for the relation between XRCC3 T241M polymorphism, adenoma (A) and CRC (B) risk in the reviewed studies. For each study,
the odds ratio for the homozygous variant genotype estimated is plotted with a box, and the area of each box is inversely proportional to the variance
of the estimated effect. Horizontal lines show 95% confidence interval. Individuals with homozygous wild-type genotype represent a referent group.
Fig. 3. Odds ratios for the relation between XRCC1 R399Q polymorphism, adenoma (A) and CRC (B) risk in the reviewed studies. For each study,
the odds ratio for the homozygous variant genotype estimated is plotted with a box, and the area of each box is inversely proportional to the variance
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Taiwan (the same population size and same poly-
morphisms in both studies). The NER XPD K751Q
polymorphism did not show any association with CRC.
The authors also analyzed this polymorphism in
combination with other two of genes involved in
different DNA repair pathways. They found that the
751Q allele, when present in individuals with XRCC1
399RR and XRCC3 241MM genotypes, moderately
increased risk of CRC (OR, 2.43; 95% CI 1.21–4.90);
particularly among younger individuals and for rectal
cancer cases. In a recent study, Yeh et al. combined the
results for biotransformation and DNA repair poly-
morphisms in the same cohort [67]. A combination of
risk genotypes for XPD K751Q, CYP1A1*2C and
GSTT1 have been associated with increased CRC risk in
males (Ptrend < 0.01).
Starinsky et al. [68] published a peculiar study on
several SNPs in different genes, including XPD K751Q,
relevant for CRC. They analyzed a heterogeneous
population from Israel (456 cases and 87 controls),
composed mainly of patients of Ashkenazi origin
(64.25%). It is not a true case-control study, since the
authors stratified the cases into two subgroups (with
follow-up): below and up the arbitrarily chosen age of
diagnosis of 50 years. SNPs were tested within
candidate genes in association with key phenotypic
features in CRC patients. No association was found for
the XPD polymorphism, except when the analyses were
limited to the Ashkenazi subgroup, in which the Q allele
was associated with higher age at diagnosis. The above
population is known to have particular genetic
characteristics.
In the study of Mort et al. [69], several SNPs were
analyzed in XPD, XPG, XPF and ERCC1. No effect was
observed for any of these NER SNPs in a British
population of a very limited size (45 cases and 71
controls, not all assayed for all SNPs). The results are
presented only as allelic frequencies for cases and
controls and not in terms of number of individuals with
a specific genotype. Besides, analyzed polymorphisms
are not very clearly specified and described (i.e. they are
presented only with the exon position, without reference
for codon, base-change, etc.). All these aspects make a
comparison with the other studies very difficult.
Recent association studies of Skjelbred et al. [70,71]
were based on the same population of cases (carcino-
mas, and diagnosis-based high- and low-risk adenomas)
and healthy controls from Norway (for details see
Table 2). No significant association with CRC was
found for the NER polymorphisms included in each
study (XPD K751Q and ERCC1 N118N). However, a
significant association between XPD 751Q allele and
risk of adenomas was reported, but significancy was
limited only to the low-risk adenoma group (OR, 1.40;
95% CI, 1.03–1.89) [71]. These limited associations
may be ascribed for following reasons. Firstly, the
authors hypothesized that this particular XPD poly-
morphism may be of importance for arresting the
adenoma–carcinoma sequence in the low-risk phase and
facilitate regression of adenomas. The second is that the
carcinoma group, as well as the high-risk adenoma
group sample size was still too small to draw any
conclusion. In the second study, ERCC1 N118N
polymorphism and risk of adenomas and CRC were
investigated in the same cohort. No significant
association was found. The authors tested the gene-
environment interactions between the haplotype of
three polymorphisms included (ERCC1 of NER path-
way plus other two SNPs in two genes connected with
cell cycle control located on the same chromosome of
ERCC1), cigarette smoking and alcohol intake. No
significant associations were found. According to the
authors, the cases and controls were matched by sex, but
not by age [70].
The largest study by the number of individuals (772
cases and 777 controls) showed no association for any
of the 15 polymorphisms in seven NER genes analysed
with colorectal high-risk adenomas [72]. However, after
considering smoking status, the three linked nonsynon-
ymous SNPs in XPC (R492H, A499V, and K939Q)
showed to modulate smoking related risk for adenoma.
In particular, XPC 492R, 499A, and 939Q alleles were
associated with an increased risk. The results are
supported by a proper design of the study (large size and
matching) and by the selection criteria for patients and
controls (controls are without evidence of a polyp or
other colon lesions). Although the population consisted
of different ethnic groups (among which Caucasians
represented a majority), authors included this variable
into the statistical analysis.
Bigler et al. [73] evaluated the associations between
XPD D312N, K751Q and XPG D1104H, and risk of
colorectal adenomatous or hyperplastic polyps. The
study was conducted on a quite large population of
patients with different diagnosis (305 with adenomatous
polyps, 196 with hyperplastic polyps and 122 with both
types of polyps) and 621 polyp-free controls by
colonoscopy. Adenomatous polyp risk was significantly
increased in individuals with the homozygous variant
XPD-combined genotypes (i.e. with at least two variant
alleles of these polymorphisms; OR, 1.57; 95% CI,
1.04–2.38). Age stratification showed that the XPD
association was limited to the subjects 60 years old
(OR, 3.77; 95% CI, 1.94–7.35). On the other hand,
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individuals carrying XPG 1104 HH genotype showed a
significantly decreased risk of developing hyperplastic
polyps (OR, 0.36; 95% CI, 0.13–0.98). This association
was observed predominantly in subjects <60 years old
(OR, 0.20; 95% CI, 0.05–0.91). The studied individuals,
recruited in the USA, were not specified for the
ethnicity (Caucasians, Afro-Americans, etc.), which
may inflate the results. Concerning modifiers, heavy
smokers with homozygous variant genotype for both
XPD polymorphisms, or wild type for XPG, had a
significantly increased risk of adenomatous polyps (OR,
3.93; 95% CI, 1.68–9.21 and OR, 1.59; 95% CI, 1.01–
1.25, respectively), compared with non-smokers with
wild type genotype. Other interactions, like alcohol,
meat consumption or vitamin intake, were not
associated with any of the different types of polyps.
The outcomes from association studies on poly-
morphisms of NER genes do not show any strong and
straight association with CRC risk. The most frequently
studied, XPD K751Q, provided significant associations
only with adenomas (Fig. 2). In CRC development the
susceptibility may play a more relevant role in the stage
of adenomas, which preceeds the onset of cancer.
3.2. Base excision repair (BER)
The BER pathway operates on small lesions such as
oxidized or reduced bases, fragmented or nonbulky
adducts, or those produced by methylating agents. The
single damaged base is removed by base-specific DNA
glycosylases (e.g. OGG1). The abasic site is then
restored by endonuclease action in a sequence of steps,
which includes removal of the sugar residue, DNA
synthesis using the other strand as a template, and
ligation [58]. Molecules involved in the restoration
phase of BER include apurinic/apyrimidinic endonu-
clease (APE1), polynucleotide kinase, DNA polymer-
ase-b, and XRCC1 [41,58].
The complete list of BER genes/polymorphisms
analysed in the association studies is reported in
Table 1. Table 3 reviews the 12 studies including one or
more polymorphisms of this particular DNA repair
pathway. Among 12 BER polymorphisms investigated
by Moreno et al. [63], the S326C variant of OGG1 was
the only one associated with an increased risk of CRC
(OR, 2.31; 95% CI, 1.05–5.09; P = 0.031, for the
recessive model combining wild type and heterozygous
genotypes). This association was stronger in younger
individuals (Pinteraction = 0.01). A significant association
was observed for the R allele of POLB P242R
polymorphism with decreased CRC risk (OR, 0.23;
95% CI, 0.05–0.99; P = 0.038). However, the R allele is
very rare; there were few individuals with heterozygous
and none with homozygous variant genotype. Three
XRCC1 SNPs (R194W, R280H, and R399Q) were
evaluated as well, but no significant association was
observed. Only for R194W and R280H polymorphisms
a significant interaction with age (P = 0.04; P = 0.05;
respectively) was found: the variant allele for both
polymorphisms was associated with a decreased CRC
risk among individuals 54 years, when compared to
those aged 70 years.
A Korean study [74] evaluated the same three
XRCC1 SNPs in association with CRC risk. Individuals
carrying the 399Q allele had a higher risk than those
carrying the 399RR genotype (OR, 2.00; 95% CI, 1.15–
3.47; P = 0.047). A significant association between the
combined alleles 194R-280R-399Q and an increased
risk for CRC was found (OR, 1.59; 95% CI, 1.01–2.49).
Alcohol intake was significantly associated with
increased CRC risk (OR, 2.60; 95% CI, 1.46–4.62;
P = 0.001). In particular, this association was observed
in individuals with combined alleles 194W-280R-399R,
194W-280H-399R, and 194R-280R-399Q.
Yeh et al. [65–67] observed no association for
XRCC1 R399Q with CRC risk, except for younger
subjects (60 years) with the 399RR genotype,
compared to those with 399Q allele (OR, 1.46; 95%
CI, 1.06–2.99; P = 0.02). A slightly increased CRC risk
appeared for individuals with the combination of
XRCC1 399RR, XRCC3 241MM and XPD 751Q
variant allele genotypes. These results are in agreement
with a general idea that susceptibility to cancer may be
modulated by some particular combinations of ‘‘unfa-
vorable’’ polymorphisms, although the gene–gene
interactions are still quite difficult to explain at the
current state of our knowledge.
There are six other studies including at least one of
the three XRCC1 polymorphisms (R194W, R280H, and
R399Q) [64,69,75–78]. Briefly, the majority of them did
not find any association with CRC risk, except for
[75,77]. These studies present their major weakness
either in the size of individuals genotyped (48 cases and
48 controls, 51 cases and 100 controls, respectively) or
in the way the data were evaluated [77].
Skjelbred et al. [71] also evaluated the possible
associations of the same three XRCC1 SNPs with
adenoma and CRC risk. The 280H allele was associated
with enhanced risk for adenomas (OR, 2.30; 95% CI,
1.19–4.46). A significant protective effect was found for
carriers of the XRCC1 399 variant allele in the high-risk
adenomas (OR, 0.67; 95% CI, 0.46–0.96). Haplotypes
in XRCC1 were tested without a significant outcome.
The presence of 399Q allele conferred a reduced risk of
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high-risk adenomas (OR, 0.62; 95% CI, 0.41–0.96).
This last result is in agreement with findings from Stern
et al. [79], who found an inverse association between
XRCC1 399QQ genotype and adenoma risk in a
population of more than 700 cases and 700 controls.
OGG1 is another BER gene very frequently
investigated in association studies on CRC. The results
on OGG1 S326C SNP, a part of a large study, were
mentioned above [63]. Goodman et al. [64] found a
significant trend for the same SNP only in some
statistical models, so, in agreement with the author,
results should be considered as inconclusive.
Hansen et al. [78] investigated OGG1 S326C in
Norwegian adenoma and CRC patients and healthy
controls (see also [70,71]). Carriers of the 326C variant
allele had a lowered risk of CRC, whereas no
association was found for the risk of adenomas. The
same polymorphism in Kim et al. [76] did not show any
independent association in a Korean population of 125
colon carcinoma cases and 247 cancer-free controls.
However, the meat intake tended to increase OR for
colon cancer (OR, 1.72; 95% CI, 1.12–2.76), the
tendency being more prominent in CC carriers (OR,
4.31; 95% CI, 1.64–11.48). Similar results were found
for smoking (increased OR for smokers carrying CC
genotype, 2.75; 95% CI, 1.07–7.53). Kim et al. [80]
published a large study (500 sporadic CRC, 124 familial
CRC and 524 healthy controls) investigating a rare
OGG1 polymorphism (R154H). This SNP was mod-
erately associated with sporadic CRC (OR, 3.586; 95%
CI, 0.98–13.11, P = 0.053). Above result raises the
possibility that OGG1 R154H may function as a low/
moderate-penetrance modifier for CRC development.
For BER pathway, the majority of studies analyzed
variants in XRCC1. For XRCC1 R399Q there is a slight
prevalence of studies with an increased CRC risk in
association with the variant Q allele, while for adenoma
cases the same allele shows a decreased risk (Fig. 3a and
b). The CRC studies are focused on different ethnic
groups and, unfortunately, positive associations emerge
mostly in studies with smaller sample-size. This
precludes a clear interpretation of the role of this
polymorphism. For two other XRCC1 SNPs (R194W,
R280H) significant associations have been observed
only in combinations, suggesting a more relevant role of
particular haplotypes rather than single SNPs. The
second most frequently analysed SNP, OGG1 S326C,
provided inconclusive outcomes. The variant allele has
been described in association with either increased
[63,64] or decreased CRC risk [78], and also in no
association at all [76]. Several studies analysed
interactions between BER SNPs with modifiers (age,
gender, smoking habit, alcohol and meat consumption).
Overall, age stratification appears to be important: an
influence of genetic polymorphisms seems to be more
relevant in individuals with younger age at the diagnosis
(i.e. below 60 years).
3.3. Double-strand breaks repair (DSB repair)
Double-strand breaks (DSBs) are produced by
replication errors and by exogenous agents, such as
ionizing radiation. DSBs repair is intrinsically more
peculiar since no undamaged template is available [81].
At least two pathways of DSB repair are arbitrarily
recognized: the homologous recombination (HR) path-
way and the non-homologous end-joining repair
(NHEJ) pathway. In the HR, DNA ends are resected,
the newly exposed 30 single-stranded tails then invade
the double helix of the homologous, undamaged partner
molecule, strands are extended by DNA polymerase,
then cross-over yield two intact DNA molecules. This
pathway involves more than 16 proteins, including
products of the breast cancer genes BRCA1 and BRCA2
and XRCC3. The NHEJ involves direct ligation of the
two DSB ends and also involves numerous molecules
[82].
Table 4 presents all studies on one or more
polymorphisms of DSB repair genes. Table 1 lists
genes/polymorphisms of this pathway. Mort et al. [69]
observed a significant over-representation of XRCC3
241T allele in CRC patients compared to controls (OR,
1.52; 95% CI, 1.04–2.22). Completely opposite results
for the same SNP were found by Jin et al. [83] in a 140
CRC cases and 280 cancer-free controls from China.
Carriers of the variant M allele showed a higher CRC
risk (OR, 3.13; 95% CI, 1.41–6.95). Similar outcome
was reported by Krupa and Blasiak [77] with a
surprisingly strong association (OR, 9.45; 95% CI,
8.77–11.65). All other studies did not find any
association for this polymorphism [63–67,71,79]. Only
one study explored other SNPs in XRCC3 (4541
A! G, 17893 A! G) on 932 adenoma cases and 1282
controls from the USA [84]. No association between
these SNPs and colorectal adenoma was recorded.
Other polymorphisms of DSB genes were included
in three studies [63,64,84]. XRCC2 R188H did not show
any significant association with colorectal adenoma risk
[84] and with CRC risk [63]. In the latter study, no
association was found for XRCC9 (T297I). The authors
indicated that both polymorphisms are rare (especially
XRCC9 polymorphism) and further studies on larger
populations are necessary to reach a sufficient statistical
power and representation of all genotypes. NBS1
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E185G is another SNP investigated in DSB genes. No
association of above SNP with colon cancer risk was
reported on 216 male cases and 255 male controls [64].
In summary, no strong associations emerged for DSB
gene polymorphisms from the reviewed studies (Fig. 4a
and b). XRCC3 T241M polymorphism was associated
with CRC risk, but with opposite directions, as reported
in [69,77,83]. Conflicting data from association studies
between polymorphisms and cancer susceptibility are
not unusual and often result from insufficient sample
size ([69,77] investigated far less than 100 patients). No
main interactions of modifiers (i.e. smoking, alcohol,
meat consumption, fatty acids and antioxidants intake)
emerge with SNPs in DSB repair genes. In the study of
Jin et al. [83], the carriers of XRCC3 241M allele non-
smokers and non-alcohol drinkers, showed an increased
CRC risk (adjusted OR 4.85, 95% CI: 1.59–14.76
among non-smokers and adjusted OR 3.72, 95% CI:
1.48–9.39 among non-alcohol drinkers, respectively).
In this case, the stratification reduced drastically the
number of observations within each group. Yeh et al.
[65–67] did not find any association for XRCC3 T241M,
but a stratification of the patients for meat consumption
revealed that individuals with 241TT genotype and low
consumers of meat had an increased risk of CRC (OR,
2.34; 95% CI, 1.28–4.29, Pinteraction = 0.02). Particu-
larly enhanced risk was recorded in rectal cancer
patients. In [67], the combination of XRCC3 T241M
wild type genotype and CYP1A1*2C variant GG
genotype was associated with increased CRC risk in
women (OR, 3.1, 95% CI, 1.3–7.0, P < 0.01). In this
case the stratification for dietary/lifestyle risk factors
and gender was justified by the large size of the cohort
(>700 individuals). The effect of age did not emerge,
except for [83], where XRCC3 241M allele was
associated with CRC risk among older individuals
(>60 years).
3.4. Mismatch repair (MMR)
Specific sequence motifs comprised of dinucleotide
repeats are known to be unstable in some human cancer.
This phenotype of ‘‘microsatellite instability’’ is caused
by defects in MMR in HNPCC and in a variety of
sporadic cancers. MMR removes nucleotides mispaired
by DNA polymerases and insertion/deletion loops that
result from slippage during replication of repetitive
sequences or during recombination. Defects in this
system dramatically increase mutation rates, accelerat-
ing the process of oncogenesis [41]. Several genes are
involved in MMR, including hMLH1, hMSH2, hPMS2,
and hMSH6 [6].
To our knowledge, there are five studies investigating
the role of MMR polymorphisms for sporadic CRC
susceptibility (Table 5). Analysed genes/polymorph-
isms are shown in Table 1.
Berndt et al. [85] investigated four SNPs in three
MMR genes in a fairly similar population as in [62].
hMSH3 1036A variant allele was associated with an
increased CRC risk (Ptrend = 0.02). After stratification
for tumor localization, hMSH3 940Q variant allele was
associated with an increased risk of proximal colon
cancer and hMSH6 39E variant allele with an increased
risk of rectal cancer (Ptrend = 0.005 and Ptrend = 0.04,
respectively). Haplotype containing the variant allele at
both hMSH3 loci was associated with an increased risk
of proximal colon cancer (Ptrend = 0.04). Stratification
for dietary habits revealed that individuals with
haplotype including one copy of both hMSH3 1036A
and 940Q variant alleles and higher daily processed
meat intake (>10.1 g/day) exhibited increased CRC
risk (Pinteraction = 0.002).
In a Korean population of 330 healthy individuals,
107 sporadic CRC patients and 107 of their first-degree
relatives, Kim et al. [86] did not find any association of
four SNPs (hMLH1 (I219V, V384D) and hMSH2
(L390F, gIVS12)) with sporadic CRC risk.
Yu et al. [87] investigated hMLH1 (93G! A and
I219V) and hMSH6 (G39E) polymorphisms for
association with risk of adenomas. Multivariable-
adjusted OR of combined heterozygous and homo-
zygous variant showed no association for the three
SNPs in three groups of cases (401 adenoma cases, 195
hyperplastic polyp cases and 123 cases with adenoma
and hyperplastic polyps; 624 polyp-free controls). No
association was found with any of the possible hMLH1
haplotypes. The risk of hyperplastic polyps differed
significantly between individuals with hMLH1 93GG
and 93AA + AG genotypes when evaluated in
interaction with smoking habit (Pinteraction = 0.02).
The population consisted mainly of Caucasians
(97%), an adjustment for ethnicity did not change the
outcome.
The study by Starinsky et al. [68] included one MMR
SNP (hMSH2 G322D), but no results are provided.
Exonuclease 1 (EXO1) gene product interacts
directly with MMR proteins MSH2, MSH3 and
MLH1 in human cells and several mutations at this
gene are peculiar of HNPCC patients [88]. Yamamoto
et al. [89] have investigated the relationship between
two EXO1 SNPs (T439M, P757L) and the development,
progression and metastasis of sporadic CRC. In a
Japanese population (102 cases and 110 controls) they
have found an association between M allele of EXO1
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T439M and increased risk of CRC (OR, 2.37, 95% CI,
1.23–4.56, P = 0.01). Additionally, patients with EXO1
757LL genotype exhibited a reduced risk of CRC by
considering PP and PL genotypes as referent (OR. 0.40,
95% CI, 0.18–0.87, P = 0.02). Individuals carrying
putative risk genotypes for both polymorphisms (TM
and MM for EXO1 T439M and PL for EXO1 P757L)
were at five-fold higher risk of CRC (P = 0.007).
Peterlongo et al. [90] evaluated two SNPs in the
hMSH6 gene (159C! T and V509A) for association
with sporadic CRC. No association for any of these
SNPs was observed in 167 CRC cases and 190 controls
(American–Jewish cohort).
There are still limited data on MMR polymorphisms
and CRC risk for drawing any conclusion at present.
[85] found significant associations with hMSH3 SNPs
and [87] found a possible modifying effect of smoking
for hyperplastic polyp risk in hMLH1 93A carriers.
Otherwise, the studies did not reveal clear positive
associations. Interestingly, polymorphisms in EXO1
seem to modulate inversely CRC risk, but only one
study is available [89] and these results should be
confirmed on larger, ethnically homogeneous popula-
tions.
3.5. Direct repair
O6-methylguanine methyltransferase (MGMT) is a
ubiquitous repair protein, vital in minimizing the
mutagenic effects of alkylating agents, covalently
binding at O6 position of guanine. MGMT acts as a
single protein that reverses alkylation damage, catalyz-
ing the transfer of alkyl groups from guanine to an
active site of cysteine [91]. MGMT participates in a
single reaction only, and is thereby irreversibly
inactivated [92].
Four studies have analysed MGMT polymorphisms
in relation to CRC risk (Table 6). The association
between MGMT I143V and L84F polymorphisms and
risk of CRC was assessed in two American nested case-
control studies [93]. The first population consisted of
197 women with CRC and 2,500 cancer-free women,
while the second included 271 male CRC cases and 451
cancer-free men as control group. Cases were matched
with controls for age and smoking history. A significant
inverse association between the MGMT 143V allele and
CRC risk was found only in women. No association was
found for MGMT L84F. After the stratification for
smoking, alcohol intake, body mass index (BMI),
postmenopausal hormone use, folate and meat intake
(the last five factors were analysed only in women), an
increased CRC risk was found among women carrying
the 84F allele and consuming more than a 0.5 alcoholic
drink/day (Pinteraction = 0.03). A BMI25 was inversely
associated with CRC risk only among women carrying
84P allele (Pinteraction = 0.04), whereas women with
143V allele and BMI 25 had a reduced risk of CRC
(OR, 0.38; 95% CI, 0.18–0.76). A significant interaction
was also found between MGMT L84F polymorphism
and postmenopausal hormone use (Pinteraction = 0.03). A
previously postulated inverse association between
current postmenopausal hormone use and risk of
CRC [94] was partially confirmed only among females
bearing MGMT 84LL genotype (OR, 0.52; 95% CI,
0.34–0.80). In postmenopausal women, MGMT 143V
allele significantly reduces the risk of CRC and
increases the protective effect of postmenopausal
hormone use among current users.
No association was found in the other studies on
MGMT polymorphisms [63,64,73], however, the data
available are still relatively scarce, precluding any
conclusion.
3.6. Pharmacogenomics and CRC: prognosis and
individual susceptibility
The prognosis of a patient with CRC is highly
impacted by various factors at the time of diagnosis,
such as localization of the tumor, quality of surgical
procedures, gender, age, and patient’s overall perfor-
mance status [95]. A significant impact on the
development of more efficient/less toxic treatment
strategies is represented by proper information on the
clinical/pathological staging and the possibility to
identify cancer patients with high likelihood of
recurrence, or experiencing clinical toxicity. Interindi-
vidual variations in response and toxicity to a particular
therapy may be due to genetic alterations in drug
targets, metabolizing enzymes, efflux and DNA repair
systems at the genomic, mRNA and protein levels.
Thus, the main aim of pharmacogenetics screening
before treatment is, on the base of the patient’s genetic
information, the identification of individual response to
particular chemotherapeutic agents [96,97]. Determina-
tion of genetic polymorphisms is becoming important
approach to design a personalized therapy and to
provide crucial information for drug development.
Presently, only a few promising polymorphisms have
been identified, or at least tested, for chemotherapy
success and toxicity in CRC treatment. The most
studied polymorphisms are in the thymidilate synthase
(TS) gene, the main target of chemotherapeutic agents
such as 5-fluorouracil and capecitabine, widely used in
CRC treatment [95]. DNA repair polymorphisms have
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also been investigated in relation to platinum agents,
cisplatin and oxaliplatin, since DNA repair capacity
modulates the chemoresistance to platinum-based
compounds [96]. Particularly enzymes of NER pathway
repair DNA damage caused by platinum agents and
several studies demonstrated the inverse relationship
between impaired DNA-repair capacity and increased
response rates to platinum drugs [98].
Three studies addressed the possible modulating role
of different DNA repair polymorphisms in relation to
the response to 5-fluorouracil/oxaliplatin treatments. In
73 patients with metastatic CRC three common XPD
polymorphisms (C156A, D312N, and K751Q) were
investigated for their possible impact on the outcome of
the therapy [99]. Concerning XPD K751Q, 5 out of 21
(24%) patients with the 751KK genotype responded,
versus 4 out of 39 (10%) with 751KQ, and 1 out of 10
(10%) with the 751QQ genotypes (P = 0.015). The
median survival in months for individuals with the
751KK genotype was 17.4 (95% CI 7.9–26.5) versus
12.8 (95% CI 8.5–25.9) for those with 751KQ and 3.3
(95% CI 1.4–6.5) with 751QQ (P = 0.002). The other
two XPD polymorphisms were neither associated with
any response to 5-fluorouracil/oxaliplatin nor with
survival. Stoehlmacher et al. [100] observed an
increased risk of chemotherapy failure in individuals
with at least 1 Gln variant allele in XRCC1 R399Q (as
assayed for in 61 patients with the same therapy as
above). The role of two ERCC1 polymorphisms (codon
118 and 30-untranslated region) was recently evaluated
for the clinical outcome to platinum-based chemother-
apy in 106 patients with advanced refractory CRC
[101]. SNP in codon 118 causes a C! T substitution,
but codes for the same amino acid, asparagine, and may
be associated with differential gene expression, whereas
SNP in 30-untranslated region may affect mRNA
stability. The authors found a significant association
between the ERCC1 codon 118 polymorphism and the
clinical outcome: patients with the C/C genotype had a
median survival of 15.3 months (95% CI, 6.0–12.1)
versus 11.1 months (95% CI, 5.8–16.2) of those with C/
T and T/T genotypes. Viguier et al. [102] analyzed 91
patients treated for metastatic CRC in a retrospective
study. They observed a higher response to combined
chemotherapy of oxaliplatin/5-fluorouracil in indivi-
duals with variant T allele in ERCC1 codon 118
polymorphism, no significant differences were detected
when patients were treated only with 5-FU or with 5-FU
and irinotecan. High ERCC1 gene expression levels
were shown to be associated with shorter surviving
period in CRC patients treated with 5-FU/oxaliplatin
[103]. By the use of univariate analysis, adjusted for
age, sex, and Duke’s stage, ERCC1 19007T > C was
associated with worse prognosis of CRC (hazard ratio-
HR, 1.51; 95% CI, 1.01–2.27), while XRCC1 R399Q
(HR, 0.38; 95% CI, 0.17–0.85), XRCC3 T141M (HR,
0.66; 95% CI, 0.45–0.97), and MGMT L84F (HR, 0.14;
95% CI, 0.02–0.99) were associated with better
prognosis, particularly in patients with adjuvant
chemotherapy [63]. Gordon et al. [104] investigated
21 polymorphisms in 18 genes (cell-cycle regulation,
drug metabolism, tumor microenvironment and DNA
repair) for the risk of CRC recurrence in 90 patients
treated with 5-FU combined with radiotherapy. SNPs in
DNA repair genes (ERCC1, XRCC3, APE1 and RAD51)
did not modulate the risk of CRC recurrence.
Despite scarce information, there is growing
evidence that the ultimate goal of therapy should be
the use of anticancer drugs that comply with the genetic
profile of the patients, in order to maximize potential
response to therapy [96].
4. Discussion
Growing evidence suggests that genetic predisposi-
tion to cancer acts via a combination of high-risk
variants in a set of low- and medium-penetrance genes,
rather than via a few high-penetrance genes [105]. This
applies for sporadic CRC in particular, where a
combination of low-penetrance susceptibility alleles
and multiple environmental factors seems to be of
relevance [6]. The role of genetic variants (e.g. SNPs) in
genes encoding key players in the susceptibility to the
sporadic CRC is not satisfactorily clarified at present.
One of the key players in CRC risk seems to be MTHFR
C677T [23], along with polymorphisms in genes
involved in cell-cycle and inflammatory processes.
Recent years have also evidenced a growing attention
devoted to the role of DNA repair genes as CRC risk
modulators. Interindividual variations in DNA repair
genes may confer altered DNA repair capacity, and thus
an enhanced cancer risk [45].
In this review, we summarized the state of the art for
DNA repair genetic polymorphisms in association with
colorectal adenoma and CRC risk. Although the present
review encompasses more than 20 studies on the above
topic, the results remain inconclusive. The number of
investigated genes and related polymorphisms is
extensive (29 and 71, respectively), but only few of
them were analysed in two and more studies. In the
majority of cases, we could only report the study-
specific outcomes, while a comparison of results to
highlight general trends was not feasible. In general,
there are no strong associations between DNA repair
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SNPs and adenoma or CRC risk, observed repeatedly in
more investigations. Many studies did not reveal any
significant association at all. The majority of studies
focused on polymorphisms in BER and in NER
pathways, XRCC1 and XPD in particular. Two recent
large studies, comprising 980 cases and 1200 controls,
reported a decreased risk for adenomas in association
with XRCC1 R399Q variant allele [71,79], whereas in
considerably smaller populations CRC risk was
moderately increased in association with this variant
allele [74,75]. Variant allele in XPD K751Q was
associated with increased adenoma, but not CRC, risk
[71,73]. Discrepancies between premalignant adenoma
and CRC are difficult to explain, but adenoma risk was
studied on a significantly larger and better characterized
populations. This interesting aspect certainly deserves
proper attention in future studies.
Although there is a weak association between single
DNA repair polymorphisms, when assayed for adenoma
and CRC risk, more realistic information may be
provided by analyzing polymorphisms in combinations.
Single SNPs in low-penetrance genes are unlikely to
affect significantly the susceptibility to cancer, but an
‘‘adverse combination’’ of less favorable genetic
variants can exert and amplify a negative effect.
However, analysis of SNPs in combination reduces
the number of observations and decreases the statistical
power of the studies. Only a few studies addressed DNA
repair gene–gene interactions so far: particular combi-
nations of XPD K751Q, XRCC1 R399Q and XRCC3
T241M wild type genotypes were associated with an
increased CRC risk in a cohort of 727 CRC patients and
736 controls from Taiwan [66]. Investigations of more
SNPs in the same DNA repair gene (especially for XPD,
ERCC1, EXO1, and MGMT) are shown in Tables 2–6.
In this context, haplotype studies appear as more
informative. A haplotype, a set of closely linked alleles
(SNPs), is inherited as a unit, ultimately covering the
variability within a gene [106]. Modulating effect of
haplotypes was investigated three-times for XRCC1
combined polymorphisms (R194W, R280H and
R399Q). Specific XRCC1 haplotypes increased the risk
of CRC in interaction with alcohol intake [74], and
adenoma risk in concomitance with fatty acid intake
[79]. The same haplotype was associated with a
decreased CRC risk in young individuals only [63].
The investigation of gene-environment interactions
implies the simultaneous study of both environmental
exposure and relevant genetic polymorphisms. While
for genotyping the methods are quite accurate, a reliable
determination of the environmental exposure is both
laborious and expensive (i.e. measurement of external/
internal dose of a chemical or its metabolites) or
unreliable and non-quantitative (i.e. information based
on questionnaires only), often missing the target tissue.
Even more difficult is the characterization of individuals
for simultaneous exposures to different factors (i.e.
occupational exposure and lifestyle habits in different
combinations), with subsequent conversion into reliable
data for statistics [15]. However, it is likely that some of
the candidate low-penetrance genes may contribute to
CRC only in concomitance with certain dietary and/or
lifestyle factors. In the present review, several studies
included stratification for main modifying factors (e.g.
smoking, alcohol consumption, gender and age), while
considerably fewer studies included an analysis for
dietary habits (meat, vitamin, vegetable/folate intake,
etc.). Interactions between DNA repair SNPs, smoking,
alcohol and specific dietary intake were found
sporadically. The same situation can be observed for
gender. Several studies do not find any differences
between males and females while in [93,67] the main
associations between CRC risk and SNPs were reported
in women only. A number of studies detected a different
susceptibility according to age. Interestingly, significant
associations of particular SNPs and adenoma or CRC
risk seem to be evident more frequently in younger
individuals (<50–60 years) [63,65,66,73,75]. However,
we noticed a considerable variety in the design of the
reviewed studies, particularly concerning studied
populations. A possible comparison of results, as well
as drawing any firm conclusion, is seriously hampered
by differences/inconsistencies in following points: size
of controls and cases, combining different ethnic
groups, improper or absent matching cases and controls
for sex and age, lack of information on CRC
localization and staging and inconsistent selection
and recruitment of the control group.
Critical analysis of the reported association studies
revealed following limitations. The most important
critical point is associated with the often too small size
of cohorts of cases and controls, resulting in a low
statistical power and false, by chance, positive or
negative outcomes. Several studies are showing the bias
introduced by analyses performed in small populations
[17]. In this context, the number of studies exceeding
500 cases was currently still limited, both for colorectal
adenoma and CRC (6 and 2, respectively). An
additional important aspect concerns the inclusion
(often disproportional) of different ethnic groups into
the cases and the controls, with subsequent obscuring of
the outcomes. Different results may be expected due to
intrinsic differences in genetic background among
Caucasians, Asians, Afro-Americans and other ethnic
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groups. Only in the recent DNA repair association
studies the statistical analyses the stratification for
ethnicity were included [62,64,72,79,83,85].
The proper recruitment of cases and controls
represents another key factor, which characterizes
different studies. Whereas in adenoma and CRC
patients we can follow the use of standard criteria for
the diagnosis (e.g. colonoscopy, histological examina-
tion), a very complicated situation appears in recruited
control individuals. The use of population-based
unscreened control group does not prevent inclusion
of individuals with undetected polyps, with subsequent
attenuation of study findings. The studies including only
colonoscopically negative individuals may not be
representative of the general population. They rather
comprise individuals with any clear indication for
colonoscopy, such as putative positive family history or
any gastrointestinal problems. On the other hand, the
major advantage of this clinic-based approach is
obtaining the control group free of polyps or CRC.
Another approach is the recruitment of only cancer-free
individuals as a control population (i.e. individuals
declaring no history of cancer in the past for them and
for family, and/or individuals tested for cancer). Since it
employs directed questionnaires, the reliability of
answers should be considered. Besides, various cancer
tests (expensive and laborious) are not yet completely
reliable. Optimally, the use of two independent control
groups (one screened for colonoscopy and one
constituted by healthy general population) would
minimize biases.
Proper matching cases and controls for age and sex
was also seldomly recorded. Modulating effects of age
and sex on CRC onset may only be investigated by
comparing matched cohorts. Large-scale whole-gen-
ome association studies may also help in a future to
implement the quality of the outcomes by searching
those SNPs, which exert a real modulating effect on
CRC risk. As an example, a scan of 1467 non-
synonymous SNPs (for genes of many different
pathways) was performed on 2575 CRC cases and
2707 controls from Great Britain [107]. The final
outcome is that after correction for multiple testing one
SNP only, in a gene involved in receptor binding and
signal transduction, remained significant (AKAP9
M463I). Without any conservative analysis, 44 SNPs,
among which few involved in DNA repair, showed a
significancy of 5%. However, DNA repair SNPs,
reviewed by us, do not seem to exert any modulating
role in CRC risk [107]. Such approaches, supported by
proper design of the study and by robust statistical
analyses, are very promising, and should allow to
restrict the analyses to few relevant SNPs and to find out
replicable genotype-disease associations. Epidemiolo-
gical studies, investigating the possible associations
between common DNA repair SNPs and risk of CRC,
can provide a useful insight into the relationship
between cancer and individual susceptibility in
response to DNA damage. These studies represent an
empirical identification of associations indicating that
SNPs in candidate genes may have an impact on a
disease, independently of metabolic and other regula-
tory systems as well as of other genetic and environ-
mental variability [57]. The current challenge is
represented by the proof of the biological plausibility
for the majority of SNPs, since the phenotypic effects
and functional reflections in the majority of cases are
not known [60].
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